← Health care and life sciences companies

    Adaptimmune: company profile, size and contacts

    adaptimmune.comActiveFor profit

    Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.

    Employees
    501-1,000
    Founded
    2008
    Total raised
    $499.5M
    Monthly visits
    16,991

    Company facts

    Website
    adaptimmune.com
    Location
    Europe, Middle East, and Africa (EMEA)
    Employees
    501-1,000
    Founded
    2008 (18 years ago)
    Categories
    Biopharma, Biotechnology, Health Care, Medical
    Company type
    For profit
    Listing
    Public (NASDAQ:ADAP)
    Industry code (NAICS)
    6211 Offices of physicians; 3254 Pharmaceutical and medicine manufacturing
    Industry code (SIC)
    8000 Health services; 2834 Pharmaceutical preparations

    Founders

    • Ian LaingFounder · Adaptimmune
    • James NobleFounder · Adaptimmune

    Adaptimmune was founded in 2008 by Ian Laing, James Noble.

    Funding

    Total raised
    $499.5M
    Funding rounds
    9
    Latest round
    Post ipo debt, 2024-05
    Investors
    17
    Lead investors
    3
    Acquisitions made
    1

    Web and app presence

    Monthly website visits
    16,991
    Global traffic rank
    #1,465,603

    How Adaptimmune compares

    • Size: Adaptimmune has more employees than 90% of the 1251 health care and life sciences companies in our directory that report it.
    • Age: Adaptimmune is older than 44% of the 1166 health care and life sciences companies in our directory that report it.
    • Web traffic: Adaptimmune gets more monthly website visits than 82% of the 1233 health care and life sciences companies in our directory that report it.

    1282 health care and life sciences companies are in the directory, 61 of them in the same 501-1,000 employee range and 131 based in Europe.

    Growth outlook

    • Trend: Growing

    Adaptimmune may be growing as evidenced by the significant appreciation in its stock value, with reports indicating an impressive 58% increase this month. Analysts have also made notable upgrades to their forecasts for the company, which suggests a positive outlook on the company's financial performance. Despite the discontinuation of certain programs, the overall sentiment from shareholders appears to be positive, as indicated by reasons to smile mentioned in the news articles.

    What Adaptimmune says about itself

    “Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients” adaptimmune.com

    Adaptimmune in short

    Adaptimmune is a biopharma company based in Europe, with 501-1,000 employees, founded in 2008. Its founders are Ian Laing and James Noble and it has raised $499.5 million over 9 rounds.

    Frequently asked questions

    What does Adaptimmune do?
    Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
    When was Adaptimmune founded?
    Adaptimmune was founded in 2008, so it is about 18 years old.
    How many employees does Adaptimmune have?
    Crunchbase lists Adaptimmune in the 501-1,000 employee range.
    Where is Adaptimmune based?
    Adaptimmune is listed under Europe, Middle East, and Africa (EMEA).
    Has Adaptimmune raised funding?
    Crunchbase records $499.5M raised across 9 funding rounds, most recently post ipo debt in 2024-05.
    How do I find email addresses at Adaptimmune?
    Search the domain adaptimmune.com with the Inbound Labs Domain Search or Email Finder to see verified contacts and departments. Individual addresses are shown after you sign up.

    Similar companies

    More in Health care and life sciences companies.

    Data sources: company facts, funding and leadership from Crunchbase; website traffic estimates from Semrush (latest month); company website, checked 2026-11-10; industry codes from the US NAICS and SIC lists; comparisons calculated from the profiles in this directory.